Aehr Test Systems completes $60.0M ATM stock sale

Aehr Test Systems completed sales under its at-the-market equity offering program, generating aggregate gross proceeds of approximately $60.0 million from common stock issuances.

Rhea-AI Filing Summary

Aehr Test Systems completed sales under its at-the-market equity offering program, generating aggregate gross proceeds of approximately $60.0 million from common stock issuances. The shares were sold under an effective Form S-3 shelf registration that registered up to $100.0 million of securities, using a prospectus supplement dated April 8, 2026.

Insights

Capital markets analyst

Aehr Test Systems completes $60.0M at-the-market stock sales.

Aehr Test Systems has fully utilized its at-the-market equity offering program, selling common stock for aggregate gross proceeds of $60.0 million. These sales were made under an effective Form S-3 shelf registration that permitted issuance of up to $100.0 million of securities.

The completed at-the-market program provides additional equity capital, with pricing and exact issuance timing not detailed in the excerpt. The shares were issued pursuant to a prospectus supplement dated April 8, 2026, indicating a recently executed capital raise using an established shelf framework.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

ATM gross proceeds: $60.0 million Shelf registration capacity: $100.0 million Prospectus supplement date: April 8, 2026 +1 more

4 metrics

ATM gross proceeds $60.0 million Aggregate gross proceeds from common stock sales under at-the-market program

Shelf registration capacity $100.0 million Total securities registered on Form S-3 (File No. 333-282661)

Prospectus supplement date April 8, 2026 Date of prospectus supplement used for at-the-market sales

Other event date April 17, 2026 Date the company fully utilized its at-the-market offering program

Key Terms

at-the-market equity offering program, Form S-3, registration statement, prospectus supplement

4 terms

at-the-market equity offering program financial

"fully utilized its previously announced at-the-market equity offering program"

A program that lets a company sell newly issued shares directly into the open market at whatever the current trading price is, usually through a broker, and do so gradually over time instead of all at once. Investors care because it can dilute existing ownership and put steady selling pressure on the stock price, while giving the company a flexible, on-demand way to raise cash — like adding small amounts of water to a pool rather than dumping in a bucket.

Form S-3 regulatory

"effective registration statement on Form S-3 (File No. 333-282661)"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

registration statement regulatory

"effective registration statement on Form S-3 (File No. 333-282661)"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

prospectus supplement financial

"and the prospectus supplement dated April 8, 2026"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aehr Test Systems (AEHR) announce in this 8-K filing?

Aehr Test Systems announced it fully utilized its at-the-market equity offering program, selling common stock for aggregate gross proceeds of approximately $60.0 million. These sales were completed under an effective Form S-3 shelf registration and a prospectus supplement dated April 8, 2026.

How much capital did Aehr Test Systems (AEHR) raise through its at-the-market program?

Aehr Test Systems raised aggregate gross proceeds of approximately $60.0 million by selling shares of its common stock. The shares were issued under an at-the-market equity offering program tied to an effective Form S-3 shelf registration statement and an April 8, 2026 prospectus supplement.

What registration statement did Aehr Test Systems (AEHR) use for the $60.0M stock sales?

The company used an effective Form S-3 registration statement, File No. 333-282661, which registered up to $100.0 million of securities. The at-the-market common stock sales for approximately $60.0 million were conducted under this shelf and a related prospectus supplement.

What type of offering did Aehr Test Systems (AEHR) complete for the $60.0M raise?

Aehr Test Systems completed an at-the-market equity offering program, selling newly issued common stock directly into the market. This flexible structure allowed the company to place shares over time under its Form S-3 shelf registration and an April 8, 2026 prospectus supplement.

When did Aehr Test Systems (AEHR) report completing its at-the-market program?

The company reported that on April 17, 2026, it had fully utilized its previously announced at-the-market equity offering program. By that date, Aehr Test Systems had completed common stock sales generating aggregate gross proceeds of approximately $60.0 million under its Form S-3 shelf registration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/20/2026 - 05:28 PM EDT Learn about SEC filing dates

0001040470false00010404702026-04-172026-04-17iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

April 17, 2026

 _______________________

AEHR TEST SYSTEMS

(Exact name of registrant as specified in its charter)

California		000-22893		94-2424084
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)
400 KATO TERRACE FREMONT, CA 94539
(Address of principal executive offices, including zip code)
510-623-9400
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value$0.01 per share	AEHR	The NASDAQ Capital Market

Item 8.01. Other Events.

On April 17, 2026, Aehr Test Systems, a California corporation (the “Company”), fully utilized its previously announced at-the-market equity offering program and completed sales of shares of its common stock having aggregate gross proceeds of approximately $60.0 million. The shares were offered and sold pursuant to the Company’s effective registration statement on Form S-3 (File No. 333-282661), which registered up to $100.0 million of securities, and the prospectus supplement dated April 8, 2026.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AEHR TEST SYSTEMS
Date: April 18, 2026	By:	/s/ Chris P. Siu
		Chris P. Siu Executive Vice President of Finance and Chief Financial Officer

3

Filing Exhibits & Attachments

5 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 4.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 13.8 KB
• EX-101 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE 898 B
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 8.7 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 2.0 KB